These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35720298)

  • 1. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
    Ai Q; Chen W; Li Y; Li G
    Front Immunol; 2022; 13():840916. PubMed ID: 35720298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.
    Xiong W; Yang Z; Chen Y
    Immunotherapy; 2024 Mar; ():. PubMed ID: 38530080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
    Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
    Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
    Lin J; Lin ZQ; Zheng SC; Chen Y
    World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
    de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
    Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events.
    Tu L; Ye Y; Tang X; Liang Z; You Q; Zhou J; Pan Z
    Front Oncol; 2021; 11():757069. PubMed ID: 35004277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
    Bi H; Ren D; Wang Q; Ding X; Wang H
    Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E; Cohen JV; Mino-Kenudson M; Dougan M
    J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
    Farha N; Faisal MS; Allende DS; Sleiman J; Shah R; Farha N; Funchain P; Philpott JR
    Oncologist; 2023 Aug; 28(8):706-713. PubMed ID: 36905577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.
    Tang T; Abu-Sbeih H; Luo W; Lum P; Qiao W; Bresalier RS; Richards DM; Wang Y
    Scand J Gastroenterol; 2019 May; 54(5):538-545. PubMed ID: 31079556
    [No Abstract]   [Full Text] [Related]  

  • 20. Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review.
    Zhou Q; Qin Z; Wu G; Yan P; Wang Q; Qu J; Jiang J; Ye D
    Front Oncol; 2024; 14():1465395. PubMed ID: 39351355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.